还原型多金属氧酸盐协同光热治疗铁死亡抗菌机制的研究
Reduced polyoxometalate synergized with photothermal therapy for the ferroptosis antibacterial mechanism
刘成辉 1王亚澜 1谢艳兰 1刘佳杰 1吕明珠 1王欢 1杜国波 2雍媛1
作者信息
- 1. 西南民族大学化学与环境学院,四川 成都 610200
- 2. 川北医学院附属医院肿瘤科,四川 南充 637000
- 折叠
摘要
由于细菌感染严重威胁着公众健康,且抗生素的滥用诱导细菌产生一定的耐药性,因此有效的抑制细菌已成为当前迫切需要解决的问题.通过简单的一锅法合成了还原型多金属氧酸盐(Fe-POM),因其在近红外光区吸收强烈,具有极佳的光热转化效率和良好的光热稳定性,可作为光热剂用于光热抗菌治疗.此外,由于还原型Fe-POM具有混合价态的 Fe2+/Fe3+,不仅能够催化活性氧(ROS)的产生,促使细菌脂质过氧化(LPO)增强,而且还会消耗谷胱甘肽(GSH),进而诱发细菌铁死亡.在细菌实验中,将Fe-POM(50 μg/mL)与NIR-II光热结合协同处理细菌后,细菌的活力下降超过95%.因此,Fe-POM不仅能促进细菌诱发铁死亡机制,而且还可以作为一种光热试剂用于抗菌治疗,通过结合纳米材料和光热治疗的双重抗菌作用能够显著提高抗菌效果.
Abstract
Since bacterial infections are a serious threat to public health and the misuse of antibiotics can induce certain resist-ance in bacteria,effective suppression of bacteria has become an urgent problem.In this study,reduced polyoxometalate(Fe-POM)was synthesized by a simple one-pot method,which can be used for photothermal antibacterial therapy due to their strong absorption in near-infrared light regions,excellent photothermal conversion efficiency and favorable photothermal stability.In ad-dition,since reduced Fe-POM has a mixed valence Fe2+/Fe3+,it not only catalyzes reactive oxygen species(ROS)production and contributes to the enhancement of bacterial lipid peroxidation(LPO),but also depletes glutathione(GSH),which in turn induces bacterial ferroptosis.In bacterial experiments,synergistic treatment of bacteria with Fe-POM(50 μg/mL)combined with NIR-II photothermal decreased the viability of bacteria by more than 95%.Therefore,Fe-POM not only promotes the bacte-ria-induced ferroptosis mechanism,but also can be used as a photothermal reagent for antibacterial therapy,which can signifi-cantly improve the antibacterial effect by combining the dual antibacterial properties of nanomaterials and photothermal therapy.
关键词
Fe-POM/光热治疗/铁死亡/抗菌/纳米材料Key words
Fe-POM/photothermal therapy/ferroptosis/antibacterial/nanomaterials引用本文复制引用
基金项目
国家自然科学基金面上项目(52273304)
四川省自然科学基金面上项目(2022NSFSC0796)
中国科协青年人才托举工程项目(YESS2022-2024QNRC001)
四川省中枢神经系统药物重点实验室面上项目(230011-01SZ)
成都市科技局重点研发支撑项目(2022-YF05-02071-SN)
出版年
2024
NETL
NSTL
万方数据